Cargando…

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1

In the present study, the ability of the proteasome inhibitor bortezomib (BZ), an oxidative stress-inducing agent, to sensitize acute myeloid leukemia (AML) cells to decitabine (Dacogen(®), DAC; a DNA methyltransferase inhibitor), in terms of cell viability and differentiation, was investigated. Kas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mpakou, Vassiliki, Spathis, Aris, Bouhla, Anthi, Mpazani, Efthimia, Papageorgiou, Sotirios, Gkontopoulos, Konstantinos, Glezou, Eirini, Thomopoulos, Thomas, Foukas, Periklis, Pappa, Vasiliki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812574/ https://www.ncbi.nlm.nih.gov/pubmed/33488804 http://dx.doi.org/10.3892/etm.2021.9628

Ejemplares similares

Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate
por: Mpakou, Vassiliki, et al.
Publicado: (2017)

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021)

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report
por: Bouchla, Anthi, et al.
Publicado: (2018)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience
por: Bouchla, Anthi, et al.
Publicado: (2019)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

Primary Adrenal Lymphomas with Cushing’s Syndrome: Two Cases with Evidence of Endogeneous Cortisol Production by the Neoplastic Lymphoid Cells
por: Papageorgiou, Sotirios G., et al.
Publicado: (2023)

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis
por: Papageorgiou, Sotirios G., et al.
Publicado: (2017)

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
por: Fokoloros, Christos, et al.
Publicado: (2022)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
por: Jonas, Brian A., et al.
Publicado: (2023)

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights
por: Foukas, Periklis G., et al.
Publicado: (2018)

Erdheim–Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report
por: Papageorgiou, Sotirios G, et al.
Publicado: (2020)

Esculetin Downregulates the Expression of AML1-ETO and C-Kit in Kasumi-1 Cell Line by Decreasing Half-Life of mRNA
por: Sawney, Sharad, et al.
Publicado: (2015)

Boswellia dalzielii-Mediated Silver Nanoparticles Inhibited Acute Myeloid Leukemia (AML) Kasumi-1 Cells by Inducing Cell Cycle Arrest
por: Adebayo, Ismail Abiola, et al.
Publicado: (2020)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

On the dynamic reconfigurable implementations of MISTY1 and KASUMI block ciphers
por: Jiexian, Huang, et al.
Publicado: (2023)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Primary non-Hodgkin lymphoma of the extra-hepatic bile duct: A case report
por: Pararas, Nikolaos, et al.
Publicado: (2022)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
por: Hilberink, Jacobien, et al.
Publicado: (2023)

Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells
por: Jiang, Lei, et al.
Publicado: (2021)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Dystroglycan Depletion Impairs Actin-Dependent Functions of Differentiated Kasumi-1 Cells
por: Escárcega-Tame, Marco Antonio, et al.
Publicado: (2015)

Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management
por: Thomopoulos, Thomas P., et al.
Publicado: (2022)

Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi-1 leukemia cells
por: ZHANG, ZHI-HUA, et al.
Publicado: (2014)

CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1
por: Kataoka, Tatsuki R., et al.
Publicado: (2013)

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?
por: Bouchla, Anthi, et al.
Publicado: (2023)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

ZGDHu-1 induces G(2)/M phase arrest and apoptosis in Kasumi-1 cells
por: XIA, JUN, et al.
Publicado: (2015)

Cytotoxicity of RNase Sa to the acute myeloid leukemia Kasumi-1 cells depends on the net charge
por: Mitkevich, Vladimir A., et al.
Publicado: (2014)

Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations
por: Kasai, Fumio, et al.
Publicado: (2020)

The Cytotoxic Effects of Moringa oleifera Leaf Extract and Silver Nanoparticles on Human Kasumi-1 Cells
por: Khor, Kang Zi, et al.
Publicado: (2020)

Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses
por: Mavrogenis, Andreas F., et al.
Publicado: (2018)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6938r7pakhktiejva5eb283f15